Belgium is a real pioneer in developing stem cell therapies. TiGenix pushes this precursor position even further by presenting good results from a Phase III of its stem cell therapy (Cx601) treating Crohn’s disease.
UPDATE (article originally published on 24/8/2015): TiGenix’s Phase III results were now published in The Lancet.
Julián Panés, the global coordinator of the study, commented: ““The Lancet is one of the most highly regarded and well known medical journals in the world; we are very delighted to have the Cx601 data selected by this prestigious publication.”
See the end of the article for more details of the candidate’s development.
Founded in 2000, Leuven-based TiGenix develops stem cell therapies for autoimmune and inflammatory diseases. These are based on expanded stem cells extracted from the patient’s adipose tissue. The company has five products in development and one on the market, as shown below.
Since its €46m IPO in 2007 at a price of €5.56,